MECP2 and fragile X syndrome: Systemic treatment with the preferential mGlu2/3 receptor antagonist, LY341495, had a beneficial effect on the pathological phenotype in a mouse model of the FXS (Choi et al. 2011) and in a rodent model of the MECP2 duplication syndrome (Vermudez et al. 2022).